Efficacy and safety of Guselkumab for moderate-to-severe psoriasis: A systematic review and meta-analysis of randomized controlled trials
Keywords:
psoriasis, monoclonal antibody, interleukin-23, GuselkumabAbstract
Introduction: Psoriasis, a chronic inflammatory skin condition, affects 125 million worldwide. Current treatments provide symptomatic relief but face limitations. Guselkumab shows promise for moderate-to-severe psoriasis.
Objective: We aimed to conduct a systematic review and meta-analysis exploring the safety and efficacy of guselkumab in moderate-to-severe psoriasis.
Methods: We searched PubMed, EMBASE, and Cochrane Library for randomized controlled trials (RCTs) comparing guselkumab to placebo in moderate-to-severe psoriasis. Primary endpoints: Investigators’ Global Assessment (IGA) 0, Psoriasis Area and Severity Index (PASI) 90, and ≥1 adverse event (AE). Secondary endpoints: IGA 0/1, PASI75, PASI100, Dermatology Life Quality Index (DLQI), and ≥1 severe AE. RStudio was used for statistical analyses.
Results: We included 1607 patients from 6 RCTs. Guselkumab significantly increased odds of IGA 0 (odds ratio (OR) OR: 73.87; 95%confidence interval (CI): 32.53-167.73; P<0.00001; I2=0.0%), and IGA 0/1 (OR: 54.84; 95% CI: 24.72–121.64; P<0.00001; I2=60.1%). Also, the OR of PASI75 (OR: 58.42; 95% CI: 23.03–148.17; P<0.001; I2=70.0%), PASI90 (OR: 46.47; 95% CI: 14.23–151.76; P<0.001; I2=71.7%), and PASI100 (OR: 59.27; 95% CI: 23.17–151.61; P<0.001; I2=0.0%) were higher with guselkumab. DLQI change was greater with guselkumab (MD: -8.46; 95% CI: -10.31 – -6.62; P<0.01; I²=77.8%). No significant difference in AEs and severe AEs between guselkumab and placebo (OR: 0.92; 95% CI: 0.68–1.24; P=0.58; I²=30.9%), (OR: 1.19; 95% CI: 0.54–2.64; P=0.66; I²=0.0%). Leave-one-out analysis identified PROTOSTAR as a source of heterogeneity. Subgroup analysis showed higher IGA 0 and PASI90 ORs in adults than in adolescents/children, with no dosage-based differences in PASI90 or AE.
Conclusion: This meta-analysis suggests that guselkumab does significantly improve moderate-to-severe psoriasis, without a significant increase in AEs.
References
Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022;13:880201. DOI:10.3389/fimmu.2022.880201
Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis. Dermatol Ther (Heidelb). 2022;12(6):1289-1302. DOI:10.1007/s13555-022-00746-6
Nair PA, Badri T. Psoriasis. In: StatPearls. StatPearls Publishing; 2025. Accessed October 5, 2025. http://www.ncbi.nlm.nih.gov/books/NBK448194/
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285.
Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of Dermatology. 2018;79(2):277-286.e10. DOI:10.1016/j.jaad.2018.03.037
Armstrong AW, Puig L, Joshi A, et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatology. 2020;156(3):258-269. DOI:10.1001/jamadermatol.2019.4029
Kerut CK, Wagner MJ, Daniel CP, et al. Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness. Cureus. 2023;15(12):e51405. DOI:10.7759/cureus.51405
761061s009lbl.pdf. Accessed February 17, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s009lbl.pdf
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019;80(4):1029-1072. DOI:10.1016/j.jaad.2018.11.057
Chapter 10: Analysing data and undertaking meta-analyses | Cochrane. Accessed April 23, 2026. https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-10
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. DOI:10.1136/bmj.n160
Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the Treatment of Adult Patients with Moderate-to-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy. Canadian Agency for Drugs and Technologies in Health; 2018. Accessed October 5, 2025. http://www.ncbi.nlm.nih.gov/books/NBK534047/
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-284.
Deeks JJ, Higgins JP, Altman DG, Group on behalf of the CSM. Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Ltd; 2019:241-284. DOI:10.1002/9781119536604.ch10
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. DOI:10.1136/bmj.l4898
Prajapati VH, Seyger MMB, Wilsmann-Theis D, et al. Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of the phase 3, randomized, placebo-controlled PROTOSTAR study. Br J Dermatol. Published online December 21, 2024:ljae502. DOI:10.1093/bjd/ljae502
Ferris LK, Ott E, Jiang J, et al. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatolog Treat. 2020;31(2):152-159. DOI:10.1080/09546634.2019.1587145
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431. DOI:10.1016/j.jaad.2016.11.042
Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study. J Dermatol. 2018;45(9):1053-1062. DOI:10.1111/1346-8138.14504
Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032-1040. DOI:10.1016/j.jaci.2014.01.025
Huang K, Geng S, Tao X, et al. Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial. Chin Med J (Engl). Published online September 8, 2025. DOI:10.1097/CM9.0000000000003771
Alexis A, McMichael A, Soung J, et al. Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025;161(9):901-911. DOI:10.1001/jamadermatol.2025.1836
Stein Gold L, Gottlieb AB, Armstrong AW, et al. SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement. Br J Dermatol. Published online August 28, 2025:ljaf327. DOI:10.1093/bjd/ljaf327
Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. Journal of the European Academy of Dermatology and Venereology. 2022;36(9):1568-1577. DOI:10.1111/jdv.18218
Mortato E, Talamonti M, Marcelli L, et al. Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study. Psoriasis (Auckl). 2025;15:455-469. DOI:10.2147/PTT.S533005
Puig L, Costanzo A, de Jong EMGJ, et al. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatol Ther (Heidelb). 2024;14(9):2539-2558. DOI:10.1007/s13555-024-01245-6
Mortato E, Talamonti M, Marcelli L, et al. Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study. Dermatol Ther (Heidelb). 2025;15(5):1239-1250. DOI:10.1007/s13555-025-01394-2
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor. JNJ.com. September 29, 2025. Accessed October 5, 2025. https://www.jnj.com/media-center/press-releases/u-s-fda-approves-tremfya-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis-marking-a-first-and-only-approval-for-an-il-23-inhibitor
Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice. Clin Exp Dermatol. 2022;47(3):561-567. DOI:10.1111/ced.14979
Eyerich K, Asadullah K, Pinter A, et al. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol. 2024;160(9):953-963. DOI:10.1001/jamadermatol.2024.2463
Yamamoto T. Similarity and difference between palmoplantar pustulosis and pustular psoriasis. J Dermatol. 2021;48(6):750-760. DOI:10.1111/1346-8138.15826
Passeron T, Carrascosa JM, Warren RB, et al. A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS). Dermatologic Therapy. 2023;2023(1):9967747. DOI:10.1155/2023/9967747
Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535. DOI:10.1002/14651858.CD011535.pub5
Gordon KB, Duffin KC, Bissonnette R, et al. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015;373(2):136-144. DOI:10.1056/NEJMoa1501646
Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020;183(2):276-284. DOI:10.1111/bjd.18634
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Laura Ghanem, Antonia Moubarak, Jacinthe Khater, Ibrahim A. Yakout, Virginia Velasco-Tamariz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
